Published Date: 04 Mar 2023
A new study by Robin von Rotz and his team found that moderate doses of psilocybin for at least two weeks reduced symptoms of depression...
Read Full NewsPhase 3b study revealed Itvisma's safety and efficacy in treating spinal muscular atrophy, showing modest motor function improvements in patients previously on other therapies.
FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis
Renal Transplantation May Lower Sleep Disorder Risk Versus Dialysis
BMI, Inflammatory Bowel Disease Both Show Causal Effect on HS Development
The HCPFive: Top News for Healthcare Providers from the Week of 12/14
1.
Scientists develop scans that light up aggressive cancer tumors for better treatment
2.
Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer
3.
Patients With Melanoma Brain Mets May Fare Better With RT Before Immunotherapy
4.
Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer
5.
For Localized Prostate Cancer, HIFU Is Not Worse Than Prostatectomy.
1.
Unveiling Tumor Immunity: Pan-Cancer Proteogenomics Characterization
2.
Late Effects of Immunotherapy in Chronic Melanoma Survivorship with Repurposed Drugs
3.
Surprising Symptoms of Prostate Cancer: What You Need to Know
4.
The Immune Revolution: Neoantigen Vaccines and the Dawn of Personalized Cancer Therapy in 2025
5.
Symptoms and Causes of Phlegmasia Cerulea Dolens: A Comprehensive Guide
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
3.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
5.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation